在波士顿研究中,Selinexor剂量减少与临床结果的关联
Sundar Jagannath1, Sosana Delimpasi2, Sebastian Grosicki3
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Clinical lymphoma, myeloma & leukemia
|September 24, 2023
概括
在BOSTON试验中减少selinexor剂量改善了多发性骨髓瘤患者的治疗结果. 这种剂量修改策略提高了疗效和生活质量,同时降低了不良事件发生率.
科学领域:
- 血液学 血液学 血液学
- 临床瘤学临床瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对不良事件 (AE) 的剂量修改可以优化癌症治疗.
- 在BOSTON试验中,针对复发性/耐药性多发性骨髓瘤,研究了塞利尼克索,博尔特佐米布和德克萨米松.
研究的目的:
- 在BOSTON试验中分析降低 selinexor 剂量的疗效和安全性.
- 为了比较接受 selinexor 剂量降低的患者和没有接受 selinexor 剂量降低的患者之间的结果.
主要方法:
- 对波士顿试验 (NCT03110562) 的后期分析.
- 对195名复发/耐药多发性髓瘤患者的疗效,安全性和生活质量 (QoL) 的比较.
- 患者被随机分配到每周一次的塞利尼克索尔 (100毫克),博特佐米布和德克萨米萨.
主要成果:
- 65%的患者 (126/195) 减少了塞林克索尔的剂量 (中位数为71.4毫克/周).
- 降低剂量与更长的无进展生存时间 (16.6 vs. 9.2 个月),更高的整体反应率 (81.7% vs. 66.7%) 和改善的 QoL 有关.
- 在剂量减少后,观察到血小板缺血,恶心,疲劳,食欲下降,贫血和腹的减少率.
结论:
- 作为对AEs的反应,减少Selinexor的剂量可以提高疗效和耐受性.
- 这一策略提高了多发性骨髓瘤患者的生活质量.
- 为管理不良事件和保持治疗效益,优化塞利尼克索的剂量至关重要.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
145
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
145
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
186
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
186
Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K


